#United States #New York #Class Action #Levi & Korsinsky #Inc. #Erasca

Levi & Korsinsky Issues Alert to Erasca, Inc. Investors on Class Action Suit

Levi & Korsinsky, LLP is currently calling on investors of Erasca, Inc. (NASDAQ: ERAS) who experienced financial losses to get in touch with their firm. This notice is particularly targeted at individuals who held ERAS shares between January 14, 2025, and April 26, 2026. These investors may qualify to reclaim monetary losses and are encouraged to verify their eligibility for claims. As the lead plaintiff application deadline approaches on August 10, 2026, immediate action is strongly recommended.

Background of the Lawsuit

The alert comes on the heels of a substantial decline in Erasca's stock price, dropping approximately 53.9%, equating to a loss of about $11.59 per share. This downturn occurred after two critical corrections on April 27, 2026, which unveiled serious allegations concerning patent infringements alongside a patient death in the Phase 1 trials.

The class action claims that Erasca’s management misled investors by making unverified comparisons between their drug ERAS-0015 and the competitor’s drug RMC-6236 during the Annual J.P. Morgan Healthcare Conference. These comparisons were termed improper and created a risk for intellectual property violations, which were not communicated to the investors. This misrepresentation, as alleged, is a key element in the ongoing lawsuit.

On March 20, 2025, Erasca expanded upon these claims in its annual SEC filings, asserting that ERAS-0015 demonstrated significantly superior binding affinity ratios compared to RMC-6236, while failing to inform investors of any risks associated with intellectual property claims.

Sequence of Events Leading to the Decline

The timeline of significant events is a crucial aspect of the lawsuit:
1. January 14, 2025: Management makes initial public comparisons that assert no patentability issues.
2. March 20, 2025: The annual report reiterates and extends claims without addressing potential patent or trade secret risks.
3. January 12-13, 2026: Updates further support the comparison narrative, which coincides with a stock offering that secured approximately $258.8 million in gross revenues.
4. March 12, 2026: An identical comparison is repeated in their 2025 annual report without disclosing any material changes.
5. April 27, 2026: Two critical disclosures reveal allegations of patent infringement and a patient’s death, causing a collapse in stock value.

When market opening occurred the day after the disclosures, the price of Erasca shares plummeted from $21.49 to $10.51, leading to significant investor losses.

The Importance of Timely Disclosure

Joseph E. Levi, Esq. emphasizes that timely disclosures concerning material developments are vital for maintaining efficient and fair markets. The implications of this timeline prompt inquiries regarding whether investors received the accurate information necessary to make informed trading decisions throughout the class period.

Erasca's history of communication raises essential questions about the credibility of the claims presented to investors, and whether they were adequately informed about potential risks.

How to Participate in the Lawsuit

The firm is advising affected investors to file their claims promptly to ensure they are included in possible recovery. The process entails no upfront costs, as this type of securities class action operates on a contingency framework. Documents such as brokerage statements that detail purchase dates, share counts, and sale dates will be necessary for filing claims.

Even investors who have already sold their shares may still qualify for recovery based on their trade history during the specified period.

In addition, those aiming to become lead plaintiff should be aware of the fast-approaching deadline of August 10, 2026, to submit their interest. While being appointed as a lead plaintiff does not enhance recovery amounts, it grants the individual direct insight into the litigation process.

For further information or to reach out regarding the lawsuit, investors may contact Joseph E. Levi, Esq. directly at (212) 363-7500.

Conclusion

The urgency of the situation calls for prompt action from Erasca, Inc. investors. With critical deadlines looming, being informed of one's rights and options is essential to navigate the complexities of the ongoing class action lawsuit effectively.